CD28 and neoplasm: Upon antigen encounter, the ΔIL2RB-z (YXXQ) CAR mediated activation of the JAK-STAT3/5 pathway resulting in superior therapeutic efficacy in multiple tumor models and outperforming conventional CD28 and 4-1BB CAR T cells (41).